At 10.6% CAGR, the South & Central America Glucose Monitoring Devices Market is Projected to be Worth US$ 2795.05 million by 2030, Says Business Market Insights

According to Business Market Insights research, the South & Central America glucose monitoring devices market was valued at US$ 1,245.06 million in 2022 and is expected to reach US$ 2,795.05 million by 2030, registering a CAGR of 10.6% from 2022 to 2030. Integration of glucose monitoring devices with personal devices is a critical factor attributed to the South & Central America glucose monitoring devices market expansion.        

Integration of glucose monitoring devices with smartphones and wearable devices stands as a transformative opportunity at the forefront of diabetic care. This synergy addresses the evolving needs of individuals managing diabetes by leveraging the ubiquity of smartphones and wearable technologies. By seamlessly connecting glucose monitoring devices to these personal devices, users gain real-time access to their blood glucose data, fostering highlighted awareness and engagement in self-management. This integration not only facilitates the continuous monitoring of glucose levels but also enables users to easily track trends, set alerts, and share crucial information with healthcare providers. Mobile apps associated with these devices often offer user-friendly interfaces for data interpretation, empowering individuals to make informed decisions about their dietary choices, medication adjustments, and lifestyle modifications. Moreover, the connectivity with smartphones and wearables enhances the overall experience, promoting long-term adherence to monitoring routines. Healthcare providers, in turn, can remotely access patients’ glucose data, allowing for timely interventions, personalized treatment adjustments, and improved patient outcomes. This technological convergence aligns with the broader trend of digital health, creating a more interconnected and patient-centric approach to diabetes management. As the adoption of smartphones and wearables continues to grow globally, the integration of glucose monitoring devices with these platforms represents a strategic opportunity to enhance accessibility, engagement, and the overall effectiveness of diabetic care.

On the contrary, high cost of glucose monitoring devices hampers the South & Central America glucose monitoring devices market.  

Based on type, the South & Central America glucose monitoring devices market is bifurcated into continuous glucose monitoring devices and self-glucose monitoring devices. The continuous glucose monitoring devices held 54.8% share of South & Central America glucose monitoring devices market in 2022, amassing US$ 682.11 million. It is projected to garner US$ 1,561.49 million by 2030 to expand at 10.9% CAGR during 2022–2030. 

Based on application, the South & Central America glucose monitoring devices market is bifurcated into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held 60.3% share of South & Central America glucose monitoring devices market in 2022, amassing US$ 750.95 million. It is projected to garner US$ 1,644.01 million by 2030 to expand at 10.3% CAGR during 2022–2030.

Based on testing site, the South & Central America glucose monitoring devices market is bifurcated into fingertip testing and alternate site testing. The fingertip testing segment held 70.3% share of South & Central America glucose monitoring devices market in 2022, amassing US$ 875.77 million. It is projected to garner US$ 2,036.65 million by 2030 to expand at 11.1% CAGR during 2022–2030.

Based on end user, the South & Central America glucose monitoring devices market is bifurcated into healthcare setting and self/homecare. The self/homecare segment held 59.5% share of South & Central America glucose monitoring devices market in 2022, amassing US$ 740.95 million. It is projected to garner US$ 1,627.11 million by 2030 to expand at 10.3% CAGR during 2022–2030.

 Based on country, the South & Central America glucose monitoring devices market has been categorized into the Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 45.6% share of South & Central America glucose monitoring devices market in 2022. It was assessed at US$ 567.76 million in 2022 and is likely to hit US$ 1,319.12 million by 2030, exhibiting a CAGR of 11.1% during 2022–2030.      

Key players operating the South & Central America glucose monitoring devices market are B. Braun SE, F. Hoffmann-La Roche Ltd, Medtronic Plc, Abbott Laboratories, Ypsomed Holding AG, and GE HealthCare Technologies Inc, among others.

• In June-2022, Roche's Accu-Chek Inform II hospital blood glucose system was approved by Health Canada for intensive care use. The Accu-Chek Inform II solution has brought and continues to bring high-end laboratory standards to bedside glucose testing and helps ensure the safety of patients.
• In Oct-2022, Life Scan launched OneTouch Solutions, an eCommerce site offering a comprehensive and convenient choice of personalized wellness programs to help people manage diabetes. OneTouch Solutions is available to US consumers and offered to healthcare providers, payors, and employers as a reimbursed adjudicated option.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com